Despite noting the high unmet need in Duchenne muscular dystrophy, the FDA panel concluded that trial data lacked substantial evidence of the therapy's effectiveness.
A dose-escalation study in 24 healthy adults showed that an 810mL infusion produced results comparable to fresh frozen plasma without significant safety signals. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results